Bausch Health Companies (BHC) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Bausch Health Companies (BHC) over the past year, gaining 148.5% versus a gain of 36.3%. Over five years, XERS leads with a +682.0% price change compared with -67.4% for BHC. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $3.08 billion), about 1.0 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.9x vs 63.6x for Xeris Biopharma). Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus 0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | XERS |
|---|---|---|
| Share price | $8.22 | $16.97 |
| Market cap | $3.08B | $3.10B |
| 1-day change | -3.97% | +2.11% |
| YTD return | +18.27% | +116.18% |
| 1-year return | +36.32% | +148.46% |
| 5-year return | -67.45% | +682.03% |
| Forward P/E | 1.89 | 63.64 |
| EPS (TTM) | $-2.26 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $291.85M |
| Revenue growth (YoY) | +6.66% | +43.72% |
| Net income (latest FY) | $157.00M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | 17.66% | 8.53% |
| Net margin | 1.53% | 0.19% |
| 52-week high | $9.04 | $17.28 |
| 52-week low | $4.33 | $5.25 |
| Distance from 52-week high | -9.07% | -1.79% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +2.19% | +1.89% |
| Average volume | 3.16M | 2.86M |
| Shares outstanding | 374.27M | 182.70M |
| Employees | 20,300 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed BHC by 112.1 percentage points over the past year.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +6.66%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
BHC vs XERS FAQ
Which is bigger, Bausch Health Companies or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $3.08B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or XERS?
XERS returned +148.46% over the past 12 months, compared with +36.32% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.